Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506883 · ClinicalTrials.gov registry record · Phase 3
MPC-004 for the Treatment of an Acute Gout Flare
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
NCT00506883 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 185 participants.
The verdict
NCT00506883, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
Study Summary
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-comparison to determine the efficacy and safety of a standard-dose of colchicine (4.8 mg) versus low-dose colchicine (1.8 mg) or placebo for acute gout flares.
Interventions
- OTHER Placebo Control
- DRUG High Dose Colchicine (4.8 mg total dose)
- DRUG Low Dose Colchicine (1.8mg total dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506883
The ClinicalTrials.gov registry entry for NCT00506883 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT00506883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506883 about?
NCT00506883 is a clinical study titled "MPC-004 for the Treatment of an Acute Gout Flare". This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-comparison to determine the efficacy and safety of a standard-dose of colchicine (4.8 mg) versus low-dose colchicine (1.8 mg) or placebo for acute gout flares.
What is the current status of trial NCT00506883?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2007-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00506883?
The interventions under investigation include: Placebo Control (OTHER), High Dose Colchicine (4.8 mg total dose) (DRUG), Low Dose Colchicine (1.8mg total dose) (DRUG).
Who is sponsoring clinical trial NCT00506883?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.